Crossmark Global Holdings Inc. Sells 538 Shares of ResMed Inc. (NYSE:RMD)

Crossmark Global Holdings Inc. trimmed its position in ResMed Inc. (NYSE:RMDFree Report) by 5.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,545 shares of the medical equipment provider’s stock after selling 538 shares during the period. Crossmark Global Holdings Inc.’s holdings in ResMed were worth $1,470,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of RMD. Norges Bank bought a new position in ResMed in the 4th quarter valued at $233,966,000. Morgan Stanley raised its position in shares of ResMed by 102.4% during the 3rd quarter. Morgan Stanley now owns 2,329,618 shares of the medical equipment provider’s stock valued at $344,481,000 after buying an additional 1,178,547 shares in the last quarter. LGT Capital Partners LTD. purchased a new stake in shares of ResMed during the 4th quarter valued at $117,621,000. Hsbc Holdings PLC raised its position in shares of ResMed by 109.9% during the 3rd quarter. Hsbc Holdings PLC now owns 490,214 shares of the medical equipment provider’s stock valued at $72,785,000 after buying an additional 256,624 shares in the last quarter. Finally, UBS Group AG raised its position in shares of ResMed by 109.3% during the 3rd quarter. UBS Group AG now owns 457,717 shares of the medical equipment provider’s stock valued at $67,683,000 after buying an additional 239,001 shares in the last quarter. 54.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on RMD shares. Royal Bank of Canada raised their price objective on shares of ResMed from $187.00 to $200.00 and gave the company a “sector perform” rating in a research report on Friday, April 26th. KeyCorp raised their price objective on shares of ResMed from $227.00 to $238.00 and gave the company an “overweight” rating in a research report on Friday, April 26th. Mizuho reiterated a “buy” rating and issued a $215.00 target price on shares of ResMed in a research report on Wednesday, March 27th. Needham & Company LLC lifted their target price on shares of ResMed from $224.00 to $236.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Finally, Oppenheimer decreased their target price on shares of ResMed from $205.00 to $200.00 and set an “outperform” rating on the stock in a research report on Friday, April 26th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $202.80.

Check Out Our Latest Research Report on RMD

ResMed Stock Performance

Shares of NYSE:RMD opened at $210.91 on Friday. The company has a market cap of $30.98 billion, a price-to-earnings ratio of 32.40, a price-to-earnings-growth ratio of 2.07 and a beta of 0.68. The company has a 50-day moving average price of $203.24 and a 200-day moving average price of $186.66. The company has a current ratio of 3.04, a quick ratio of 1.97 and a debt-to-equity ratio of 0.22. ResMed Inc. has a 12 month low of $132.24 and a 12 month high of $229.97.

ResMed (NYSE:RMDGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The medical equipment provider reported $2.13 EPS for the quarter, beating the consensus estimate of $1.91 by $0.22. The firm had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. ResMed had a net margin of 20.91% and a return on equity of 24.43%. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.68 earnings per share. As a group, equities analysts anticipate that ResMed Inc. will post 7.7 EPS for the current year.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 13th. Stockholders of record on Thursday, May 9th will be paid a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a dividend yield of 0.91%. The ex-dividend date of this dividend is Wednesday, May 8th. ResMed’s dividend payout ratio (DPR) is 29.49%.

Insider Activity

In related news, CEO Michael J. Farrell sold 14,683 shares of the business’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $216.50, for a total transaction of $3,178,869.50. Following the transaction, the chief executive officer now owns 440,752 shares in the company, valued at $95,422,808. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Karen Drexler sold 425 shares of the business’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $214.92, for a total transaction of $91,341.00. Following the transaction, the director now owns 8,446 shares in the company, valued at $1,815,214.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael J. Farrell sold 14,683 shares of the company’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $216.50, for a total transaction of $3,178,869.50. Following the completion of the sale, the chief executive officer now owns 440,752 shares in the company, valued at approximately $95,422,808. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,468 shares of company stock valued at $3,348,795. Insiders own 1.21% of the company’s stock.

ResMed Profile

(Free Report)

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Featured Stories

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.